ro13-9904 and Hypersensitivity

ro13-9904 has been researched along with Hypersensitivity* in 3 studies

Reviews

1 review(s) available for ro13-9904 and Hypersensitivity

ArticleYear
Efficacy and Safety of Treatments for Different Stages of Syphilis: a Systematic Review and Network Meta-Analysis of Randomized Controlled Trials and Observational Studies.
    Microbiology spectrum, 2022, 12-21, Volume: 10, Issue:6

    Parenteral penicillin is the first-line regimen for treating syphilis. However, allergic reactions and poor drug tolerance still present challenging problems with respect to use of this antibiotic. This study aimed to evaluate the efficacy and safety of ceftriaxone, erythromycin, minocycline, tetracycline, and doxycycline for syphilis treatment, compared with penicillin, to determine which antibiotic could be a better substitute for penicillin. This study included 17 articles, comprising 3 randomized controlled trials (RCTs) and 14 observational studies and involving 4,485 syphilis patients. Estimated risk ratios (RRs) and 95% confidence interval (CIs) were used to compare the serological response rates. At the 6- and 12-month follow-ups, the serological response rates were compared by direct meta-analysis and network meta-analysis (NMA). Based on direct meta-analysis, the serological response rates at the 3- and 24-month follow-ups were compared. Our NMA showed a higher serological response rate for ceftriaxone than for penicillin at the 6-month follow-up (RR of 1.12, 95% CI of 1.02 to 1.23). Ceftriaxone was equally effective as penicillin for syphilis in terms of serological response rates, and it was a better substitute for penicillin than ceftriaxone, erythromycin, minocycline, tetracycline, or doxycycline. However, more large-scale, high-quality, double-blind trials are still needed to determine whether ceftriaxone can safely replace penicillin for the treatment of syphilis when necessary.

    Topics: Anti-Bacterial Agents; Ceftriaxone; Doxycycline; Erythromycin; Humans; Hypersensitivity; Minocycline; Network Meta-Analysis; Observational Studies as Topic; Penicillins; Randomized Controlled Trials as Topic; Syphilis; Tetracycline

2022

Other Studies

2 other study(ies) available for ro13-9904 and Hypersensitivity

ArticleYear
Stability Over Time of In-Hospital-Compounded Amoxicillin Capsules and Ceftriaxone Patch Tests for Drug Allergy Testing.
    Journal of investigational allergology & clinical immunology, 2023, 07-27, Volume: 33, Issue:4

    Topics: Amoxicillin; Capsules; Ceftriaxone; Drug Compounding; Drug Hypersensitivity; Humans; Hypersensitivity; Patch Tests

2023
A Failure of Rapid Drug Desensitization.
    Military medicine, 2023, 01-04, Volume: 188, Issue:1-2

    We present the case of a patient who was unable to tolerate rapid drug desensitization protocol to receive a continuous penicillin (PCN) G infusion for the treatment of neurosyphilis. A 38-year-old male with past medical history for human immunodeficiency virus, migraines, PCN allergy, doxycycline allergy, shellfish allergy, and untreated latent syphilis presented to the emergency room for a posterior migraine with associated nausea, vomiting, photophobia, right-sided paresthesias, and "shaky" vision. He was diagnosed with neurosyphilis and underwent rapid drug desensitization with the goal to receive a continuous infusion of PCN G. The patient's hospital course was complicated by intermittent drug reactions consisting of tachycardia, rash, and dyspnea, followed by periods of being able to tolerate the infusion. After being able to tolerate the recommended dose of PCN infusion, the patient was discharged home to complete the course. However, he returned almost immediately after a recurrence of symptoms at home requiring the use of intramuscular epinephrine. Ultimately, the patient was transitioned to ceftriaxone and completed the infusion course as an inpatient because of continued intermittent recurrence of drug reaction symptoms.

    Topics: Adult; Ceftriaxone; Drug Hypersensitivity; Drug-Related Side Effects and Adverse Reactions; Humans; Hypersensitivity; Male; Neurosyphilis; Penicillins

2023